摘要
目的初步探讨三次造血干细胞移植治疗多发性骨髓瘤的安全性及疗效。方法对我院2例多发性骨髓瘤患者三次造血干细胞移植的临床资料进行回顾性分析。2例自体干细胞动员方案均为环磷酰胺(CTX)联合粒细胞刺激因子(G-CSF),采用以马法兰和(或)硼替佐米为主的预处理方案。其中1例第3次为异基因外周血干细胞移植,余均为自体外周血干细胞移植。结果 2例患者三次造血干细胞均成功植入,无移植相关死亡。结论三次造血干细胞移植治疗多发性骨髓瘤安全、有效、可行。
Objective To evaluate the safety and efficacy of three times of hematopoietic stem cell transplan- tation in the treatment of multiple myeloma. Methods The clinical data of two patients with multiple myeloma treated with three times of hematopoietic stem cell transplantation in our hospital were analyzed retrospectively ; both of the peripheral blood stem cell mobilization regimen included CTX and G-CSF, and the pretreatment regimen consisted of melphalan and/or bortezomib. In one case, the third time was allogeneic peripheral blood stem cell transplantation, and the others were self-peripheral blood stem cell transplantation. Results Three times of hematopoietic stem cells were successfully implanted in 2 patients without transplants-related death. Conclusion Three times of hematopoietic stem cell transplantation is safe, effective and feasible for the treatment of multiple myeloma.
出处
《实用药物与临床》
CAS
2018年第1期61-63,共3页
Practical Pharmacy and Clinical Remedies
关键词
多发性骨髓瘤
造血干细胞移植
三次移植
Multiple myeloma
Hematopoietic stem cell transplantation
Three times of transplantation
